{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "PATH", "name": "UiPath, Inc.", "url": "https://frontierpicks.com/dossiers/PATH/", "json_url": "https://frontierpicks.com/dossiers/PATH.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a4", "n": 4 }, "current_thesis": "UiPath's agent-orchestration recovery case requires quantified commercial evidence at its 2026-09-22 Investor Day and a subsequent weekly close above $15. A weekly close below the September 11 reference close of $13.75 invalidates this new hypothesis; the August thesis has already failed.", "invalidation_trigger": "A weekly close below $13.75 invalidates the recovery hypothesis; this is the 2026-09-11 reference close, not established support. The 2026-09-22 Investor Day passing without quantified paid adoption or identifiable orchestration revenue separately fails its evidence requirement.", "catalyst_date": "2026-09-22", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "ai-enterprise-software" ], "tags": [], "sources": [], "notes": [ "Fiscal year ends January 31 — 'Q2 FY2027' is the quarter ended 2026-07-31, reported 2026-09-03.", "Dual-class structure: Class B shares carry 35 votes each versus one vote for the listed Class A, concentrating control with founder-insiders.", "A portion of term-licence revenue is recognised upfront, making quarterly revenue lumpy; ARR and net new ARR are the steadier series to track.", "Pre-earnings blackout ahead of the 2026-09-03 print limits insider-transaction signal through late August.", "The fiscal calendar places results outside the main September software reporting cluster, so single-name flow around the print has no peer report alongside it." ], "body_markdown": "## Current Thesis\n\nUiPath's recovery case requires quantified commercial evidence for agent orchestration at the 2026-09-22 Investor Day and a subsequent weekly close above $15; a weekly close below $13.75 would invalidate it. This is a new, low-conviction recovery hypothesis: the August thesis already failed its published $15 weekly-close condition when the shares finished 2026-09-11 at $13.75.\n\nFor the August rerating leg, the narrative is dead — the 2026-09-11 close breached its stated price condition despite better company results. The underlying business proposition remains the transition from robotic process automation to coordinating artificial-intelligence agents across enterprise workflows. Investor Day is company-confirmed for 2026-09-22; commercial adoption figures, rather than another product description, are the evidence this recovery hypothesis requires. [UiPath's August 25 announcement](https://ir.uipath.com/news/detail/458/uipath-announces-upcoming-investor-day).\n\n## Bull Case\n\n- **Results cleared the revenue hurdle.** For the quarter ended 2026-07-31, UiPath reported revenue of $410 million, up 13% year over year, and operating income under generally accepted accounting principles of $32 million. [September 3 results](https://ir.uipath.com/news/detail/461/uipath-reports-second-quarter-fiscal-2027-financial-results).\n- **The recurring business still expanded.** Annualized renewal run-rate (ARR) reached $1.938 billion at 2026-07-31, up 12% year over year; net new ARR was $37 million and dollar-based net retention was 109%. [September 3 results](https://ir.uipath.com/news/detail/461/uipath-reports-second-quarter-fiscal-2027-financial-results).\n- **Management raised the annual outlook.** On 2026-09-03, UiPath guided fiscal 2027 revenue to $1.789–1.794 billion and year-end ARR to $2.065–2.070 billion. These replace the lower May ranges in the prior research. [Company outlook](https://ir.uipath.com/news/detail/461/uipath-reports-second-quarter-fiscal-2027-financial-results).\n\n## Bear Case\n\n- **Expansion has not established acceleration.** The $37 million of net new ARR reported on 2026-09-03 was below the $49 million reported on 2026-05-28. This quarterly comparison is insufficient to establish a durable trend. [September results](https://ir.uipath.com/news/detail/461/uipath-reports-second-quarter-fiscal-2027-financial-results); May results cited in the August 30 research.\n- **Analyst enthusiasm remained divided.** Benzinga's 2026-09-04 ratings reports recorded Canaccord's downgrade to Hold with a $17 target, while Mizuho retained Neutral with a $14 target. Citigroup's September 8 initiation carried a $23 target, according to the supplied dated coverage. Those are analyst opinions, not measured commercial outcomes.\n- **The published structure already broke.** The adjusted market close of $13.75 on 2026-09-11 was below the August 30 research's $15 invalidation level. Better financial results did not preserve that price condition.\n\n## Setup & Price Structure\n\nThe supplied adjusted series records a 2026-09-11 close of $13.75, a three-month price gain of 30.3%, and a price 28.7% below its $19.29 trailing-year high. The 14-period relative strength index was 34.7 on that date. These observations establish substantial remaining medium-term gains alongside recent weakness; they do not establish a base.\n\nThe recovery hypothesis uses $13.75 strictly as the September 11 reference close, not as a demonstrated support shelf. Its price objective is a weekly close above the previously published $15 boundary, conditional on commercial evidence at Investor Day. This separate test does not reverse the recorded failure of the August thesis.\n\nPositioning evidence is limited to the September 4 cluster of analyst revisions and the September 8 Citigroup initiation reported in the supplied coverage. No dated fund-flow, short-interest, insider-transaction or moving-average series is available here. Coverage clustering alone cannot establish crowded ownership.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-22 — UiPath Investor Day.** The company announced a Las Vegas event beginning at 11:30 a.m. Pacific time. The research question is whether management supplies quantified paid adoption or separately identified commercial contribution from agent orchestration; the announcement itself promises no such disclosure. [August 25 event announcement](https://ir.uipath.com/news/detail/458/uipath-announces-upcoming-investor-day).\n\n## What Would Change Our Mind\n\nFailure to retain the September 11 reference close would end the recovery hypothesis: a weekly close below $13.75 is its price invalidation. Investor Day passing on 2026-09-22 without quantified paid adoption or identifiable orchestration revenue would separately fail its evidence requirement.\n\nThe broken August structure would warrant reassessment only after that commercial disclosure and a subsequent weekly close above $15. Neither condition is established by the September 11 price record or the August 25 event announcement.\n\n## Correlation Notes\n\nThis remains a single-name recovery hypothesis. The August 30 research attributed the August 27 advance to Salesforce's August 26 results, while the September 4 Benzinga coverage places UiPath's decline alongside its own earnings reaction. Those observations do not provide enough paired returns to estimate correlation or separate software-sector exposure from company-specific repricing. The sample is too small to support a correlation claim.", "first_seen": "2026-08-21", "last_analyzed": "2026-09-20T08:07:04+00:00", "last_synthesized": "2026-09-13", "last_update_source": "research_universe", "license": "Content © FrontierPicks. Cite the canonical URL." }